Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
Settings
EXEL Exelixis, Inc. daily Stock Chart
EXEL [NASD]
Exelixis, Inc.
Index- P/E- EPS (ttm)-0.92 Insider Own1.70% Shs Outstand227.21M Perf Week-1.73%
Market Cap1.03B Forward P/E- EPS next Y-0.86 Insider Trans-6.13% Shs Float212.09M Perf Month-14.18%
Income-184.00M PEG- EPS next Q-0.22 Inst Own71.40% Short Float27.52% Perf Quarter-26.89%
Sales34.60M P/S29.81 EPS this Y-3.80% Inst Trans0.23% Short Ratio13.52 Perf Half Y-22.92%
Book/sh-0.34 P/B- EPS next Y-2.40% ROA-60.30% Target Price11.00 Perf Year138.95%
Cash/sh0.87 P/C5.22 EPS next 5Y- ROE140.60% 52W Range1.86 - 6.81 Perf YTD-19.50%
Dividend- P/FCF- EPS past 5Y-1.80% ROI-90.80% 52W High-33.33% Beta2.32
Dividend %- Quick Ratio3.70 Sales past 5Y-30.20% Gross Margin89.60% 52W Low144.09% ATR0.41
Employees98 Current Ratio3.70 Sales Q/Q57.10% Oper. Margin- RSI (14)47.27 Volatility9.57% 10.21%
OptionableYes Debt/Eq- EPS Q/Q31.30% Profit Margin- Rel Volume1.36 Prev Close4.75
ShortableYes LT Debt/Eq- EarningsFeb 24 AMC Payout- Avg Volume4.32M Price4.54
Recom2.00 SMA200.81% SMA50-8.85% SMA200-6.94% Volume5,853,080 Change-4.42%
Jan-19-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-02-14Downgrade Stifel Buy → Hold
Feb-07-14Reiterated Stifel Buy $9 → $11
Jan-21-14Reiterated Maxim Group Buy $7.50 → $11
Nov-12-13Upgrade Maxim Group Hold → Buy $7.50
May-28-13Downgrade Maxim Group Buy → Hold $35 → $35
Nov-30-12Reiterated Stifel Nicolaus Buy $8 → $9
Apr-20-12Initiated Maxim Group Buy $9
Mar-15-12Resumed Stifel Nicolaus Buy $8
Aug-17-11Initiated Stifel Nicolaus Hold $8
Nov-18-09Downgrade Merriman Buy → Neutral
Jun-17-09Initiated Boenning & Scattergood Neutral
Dec-15-08Reiterated Lazard Capital Buy $7 → $8
Nov-24-08Reiterated Lazard Capital Buy $7
Oct-16-08Initiated Merriman Curhan Ford Buy
Aug-14-08Initiated Banc of America Sec Neutral $7
Aug-06-08Reiterated Lazard Capital Buy $12 → $10
Aug-06-08Downgrade Canaccord Adams Buy → Hold
Jul-08-08Initiated Canaccord Adams Buy $7.30
Dec-07-07Reiterated Fortis Bank Hold $10 → $9
Feb-04-16 04:05PM  Exelixis to Present at the Leerink Partners 5th Annual Global Healthcare Conference on February 10 Business Wire +7.22%
Feb-03-16 02:44PM  Forget Gilead Sciences: These Stocks Doubled Last Year at Motley Fool
Feb-02-16 04:50PM  Exelixis' Cabozantinib Positive in Renal Cell Carcinoma Study
04:17PM  Emotional Investing Deflates Exelixis, Inc. in January at Motley Fool
Feb-01-16 09:05AM  Exelixis Rises on Positive Late-Stage Trial Results at 24/7 Wall St.
08:20AM  Exelixis Announces Positive Overall Survival Results from METEOR, the Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma at noodls
08:02AM  Exelixis Kidney Cancer Survival Benefit Doesn't Address Competitive Question at TheStreet
08:00AM  Exelixis Announces Positive Overall Survival Results from METEOR, the Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Business Wire
Jan-29-16 07:48PM  Why Exelixis, Inc. Rocketed Higher on Friday at Motley Fool +10.53%
04:20PM  Exelixis's Cabozantinib Granted Priority Review in the U.S.
Jan-28-16 04:05PM  Exelixis Announces European Medicines Agency Acceptance of Marketing Authorization Application for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma Business Wire
08:00AM  Exelixis Announces U.S. FDA Deems New Drug Application Sufficiently Complete and Grants Priority Review for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma Business Wire
Jan-27-16 08:00AM  Equities Updates on Biotechnology -- Celldex Therapeutics, Amgen, Exelixis, and Ariad Pharma Accesswire -7.53%
Jan-20-16 06:00AM  [video]'Mad Money' Lightning Round: Move on From Broadcom at TheStreet +8.43%
Jan-19-16 08:07AM  Exelixis upgraded by Leerink Partners
Jan-15-16 11:56AM  Bristol-Myers Squibb: A New Chapter, and the Beginning of Sustained Growth at Motley Fool -5.58%
Jan-12-16 08:00AM  Best Small-Cap Stocks of 2015 at Motley Fool
Jan-11-16 08:30AM  Exelixis Submits Marketing Authorization Application in the European Union for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma Business Wire -5.11%
Jan-10-16 08:18AM  1 George Soros Quote to Keep in Mind in 2016 at Motley Fool
Jan-08-16 09:30AM  The Zacks Analyst Blog Highlights: AbbVie, Amgen, Ligand Pharmaceuticals, Revance Therapeutics and Exelixis
Jan-07-16 04:20PM  Why #JPM16 matters: Biotechs open news spigots ahead of big conference at bizjournals.com -6.81%
Jan-06-16 12:19PM  Exelixis, Inc. Nearly Quadrupled in 2015 -- Here's Why at Motley Fool
Jan-05-16 01:00PM  Exelixis Reveals Data on Cabozantinib for Kidney Cancer
12:35PM  Exelixis Posts Positive Late Stage Results in METEOR trial
09:09AM  Exelixis Spikes Following Phase 3 Results Of Cabozantinib; EU Filing Planned For Early 2016
Jan-04-16 05:07PM  Exelixis Announces Positive Results From Subgroup Analyses of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma to be Presented at ASCO 2016 Genitourinary Cancers Symposium Business Wire
Jan-02-16 07:40AM  The Top 5 Best Performing Biotech Stocks of 2015 at Motley Fool
Dec-31-15 07:39AM  These 3 Companies Doubled in 2015 at Motley Fool
Dec-30-15 08:08AM  Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : December 30, 2015
Dec-28-15 03:35PM  Exelixis Submits Rolling NDA for Oncology Drug in the U.S.
08:19AM  The Best Biotech Stocks in 2015 at Motley Fool
Dec-27-15 01:17PM  2 Healthcare Stocks That Dominated in 2015 at Motley Fool
08:59AM  3 Biotech Stocks Under $5 That Could Explode Higher in 2016 at Motley Fool
Dec-23-15 04:06PM  Exelixis (EXEL) Stock Spikes, Submits New Drug Application at TheStreet +10.42%
03:43PM  Why Exelixis, Inc. Is Trading Higher Today at Motley Fool
08:30AM  Exelixis Completes Submission of New Drug Application for Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma Business Wire
Dec-22-15 08:00PM  The Best Exelixis, Inc. Headlines in 2015 at Motley Fool
Dec-14-15 08:40AM  The Top 10 Stocks of 2015: Biotech Companies And Netflix at Forbes
03:40AM  The Top 10 Stocks of 2015: Biotech Companies And Netflix
Dec-10-15 11:34AM  Exelixis, Inc. Earnings Analysis: Q3, 2015 By the Numbers
10:15AM  These 3 Stocks Doubled Investors' Money This Year at Motley Fool
Dec-08-15 01:17PM  EXELIXIS, INC. Financials
Dec-01-15 08:25AM  Huge PowerShares ETF Rebalance Means Massive Buying for 4 Biotech Stocks at 24/7 Wall St.
Nov-28-15 12:46PM  What Do Hedge Funds Think of Exelixis, Inc. (EXEL)? at Insider Monkey
Nov-26-15 01:20PM  Roche-Exelixis' Cotellic-Zelboraf Combination Gets EC Nod
Nov-25-15 09:33AM  Exelixis Announces European Commission Approval of COTELLIC (Cobimetinib) for Use in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive Melanoma Business Wire
07:58AM  Here is What Hedge Funds Think About Viavi Solutions Inc (VIAV) at Insider Monkey
Nov-23-15 01:19PM  Roche & Exelixis Announce Positive Data on Cotellic & Zelboraf
09:20AM  The FDA Approves Exelixis, Inc's New Cancer Drug at Motley Fool
Nov-21-15 06:40PM  Exelixis Announces Presentation of Positive Overall Survival Results for COTELLIC in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive Melanoma at Society for Melanoma Research 2015 International Congress Business Wire
Nov-16-15 10:02AM  Did You Miss These Top Stories in Healthcare? at Motley Fool
Nov-15-15 06:00PM  Exelixis, Inc. Earnings: Riding the Meteor at Motley Fool
Nov-14-15 03:00PM  6 Stocks That Could Double In 2016 at Motley Fool
09:01AM  Are Investors Nuts To Be Short These Stocks? at Motley Fool
Nov-12-15 04:35PM  Exelixis to Present at the Stifel 2015 Healthcare Conference on Tuesday, November 17 Business Wire -5.57%
12:10PM  Exelixis, Inc. Value Analysis (NASDAQ:EXEL) : November 12, 2015
09:52AM  Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : November 12, 2015
Nov-11-15 04:23PM  Exelixis (EXEL) Stock Dropped Following Earnings Release at TheStreet -9.32%
12:16PM  Why Exelixis Shares Declined Today at Motley Fool
09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Retrophin, Exelixis, Actelion and Enzo Biochem
12:26AM  Edited Transcript of EXEL earnings conference call or presentation 10-Nov-15 10:00pm GMT
Nov-10-15 05:00PM  Exelixis Inc Earnings Call scheduled for 5:00 pm ET today
04:59PM  Exelixis (EXEL) Stock Declines in After-Hours Trading on Quarterly Loss at TheStreet
04:46PM  Exelixis reports 3Q loss
04:29PM  EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
04:27PM  Exelixis Announces Third Quarter 2015 Financial Results and Provides Corporate Update Business Wire
04:25PM  EXELIXIS, INC. Files SEC form 10-Q, Quarterly Report
02:21PM  Big new-drug win for skin cancer patients, two Bay Area biotechs at bizjournals.com
01:37PM  FDA Approves COTELLIC (Cobimetinib) for use in Combination with Vemurafenib to Treat Advanced Melanoma Business Wire
11:58AM  FDA approves Roche's Cotellic for combination skin cancer therapy Reuters
07:07AM  Q3 2015 Exelixis Inc Earnings Release - After Market Close
Nov-09-15 03:50PM  What to Expect from Exelixis (EXEL) this Earnings Season?
Nov-05-15 09:30AM  The Zacks Analyst Blog Highlights: Amazon.com, LendingTree, Dycom Industries, Exelixis and ZIOPHARM Oncology
Nov-04-15 04:12PM  5 Stocks That Doubled in 2015 -- And Keep Going Up
Nov-01-15 01:20PM  3 Biotech Stocks to Buy in November at Motley Fool
Oct-30-15 08:19AM  Why biotech could be on the verge of a rebound
Oct-28-15 09:33AM  Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : October 28, 2015
Oct-23-15 02:36PM  Exelixis Starts Cometriq Rolling NDA Filing for Kidney Cancer
Oct-22-15 08:00AM  Exelixis Initiates Rolling Submission of U.S. New Drug Application for Cabozantinib for the Treatment of Advanced Kidney Cancer Business Wire
Oct-20-15 04:42PM  Exelixis to Release Third Quarter 2015 Financial Results on Tuesday, November 10, 2015 Business Wire
Oct-12-15 04:05PM  Exelixis, Medicines Company Trade above 100-Day Moving Averages
Oct-09-15 02:03PM  How Much Could Exelixis Really Be Worth? at Motley Fool
Oct-08-15 04:55PM  Roche (RHHBY) Reports Positive Data on Skin Cancer Drugs
10:43AM  Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : October 8, 2015
Oct-06-15 01:17AM  Roche says data shows Cotellic combination therapy effective Reuters
01:00AM  Exelixis Announces Positive Overall Survival Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma Business Wire
Oct-04-15 01:20PM  Kidney Cancer Drug Boxing Match at Motley Fool
Sep-30-15 04:36PM  10 Best Nasdaq Biotech Stocks in the Third Quarter at TheStreet
Sep-29-15 02:46PM  4 Stocks Under $10 Making Big Moves Higher at TheStreet
01:03PM  Don't Panic! These 3 Beaten Down Biotech Stocks Are Now Great Buys at Motley Fool
Sep-28-15 09:37AM  Stocks to Watch: Alcoa, Apple, Cal-Maine, Media General at The Wall Street Journal
07:23AM  Two Kidney Cancer Drugs Show Promise in Separate Studies at The Wall Street Journal
Sep-26-15 12:30PM  Exelixis Inc Investor/Analyst Webcast to Review METEOR Data Call scheduled for 12:30 pm ET today
01:25AM  Two Kidney Cancer Drugs Show Promise in Separate Studies at The Wall Street Journal
Sep-25-15 06:09PM  Exelixis Announces Positive Results from METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Presented at European Cancer Congress 2015 Business Wire
06:02PM  Bristol, Exelixis Drugs Demonstrate Treatment Benefit in Kidney Cancer at TheStreet
06:01PM  Bristol-Myers Kidney Cancer Drug Boosts Survival in Big Study at Bloomberg
07:41AM  European CHMP Adopts Positive Opinion for Cobimetinib in Combination with Vemurafenib for the Treatment of Advanced Melanoma Business Wire
Sep-24-15 08:00AM  Exelixis Announces Key Senior Leadership Hires in Medical Affairs, Sales, and Marketing to Support Commercialization of Cabozantinib and Cobimetinib Business Wire
Sep-22-15 05:08PM  Exelixis to Host Investor/Analyst Webcast During European Cancer Congress 2015 Business Wire
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer. It is also evaluating cabozantinib in various development programs comprising approximately 45 clinical trials, including 2 ongoing phase 3 pivotal trials focusing on metastatic renal cell carcinoma (mRCC) and advanced hepatocellular carcinoma (HCC). In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase 3 pivotal trial evaluating in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WILLSEY LANCEDirectorDec 11Buy4.7850,000239,000494,975Dec 11 07:43 PM
WILLSEY LANCEDirectorDec 10Buy4.9950,000249,550444,975Dec 11 07:43 PM
Lamb PeterEVP, Discovery Research & CSOOct 16Option Exercise5.6351,549290,22188,022Oct 19 05:08 PM
Lamb PeterEVP, Discovery Research & CSOOct 16Sale5.8051,549298,98436,473Oct 19 05:08 PM
Lamb PeterEVP, Discovery Research & CSOOct 13Option Exercise5.636003,37837,073Oct 14 05:05 PM
Lamb PeterEVP, Discovery Research & CSOOct 13Sale5.806003,48036,473Oct 14 05:05 PM
Lamb PeterEVP, Discovery Research & CSOOct 12Option Exercise5.63300,2761,690,554336,749Oct 14 05:05 PM
Lamb PeterEVP, Discovery Research & CSOOct 12Sale5.84300,2761,753,31236,473Oct 14 05:05 PM